Journal article icon

Journal article

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.

Abstract:

BACKGROUND: B-type CpG oligodeoxynucleotides (ODN) is currently used in clinical trials because of its prolonged half-life, which is due to its phosphorothioate backbone. A-type CpG ODN is a stronger inducer of IFN but has an unstable phosphodiester backbone that has so far prohibited its clinical use. However, upon association with virus-like particles (VLP) consisting of the bacteriophage Qbeta coat protein, A-type CpG ODN can be stabilized and can become an efficient adjuvant in mice. The...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Journal:
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology More from this journal
Volume:
39
Issue:
4
Pages:
562-570
Publication date:
2009-04-01
DOI:
EISSN:
1365-2222
ISSN:
0954-7894
Language:
English
Keywords:
Pubs id:
pubs:422391
UUID:
uuid:ad9778fa-9a1f-4d51-8972-9bb3698c0564
Local pid:
pubs:422391
Source identifiers:
422391
Deposit date:
2014-06-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP